What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over with BTC. Participants enrolling in Part A the trial will be randomly assigned to receive 1 of 3 nanvuranlat dose regimens or PBC. In Part B, participants will be randomly assigned to receive nanvuranlat or PBC. Participants will receive treatment every 2 weeks for as long as they do not experience safety issues, or their cancer gets worse, and the study doctor feels…”In the company’s words, NCT07265674 on ClinicalTrials.gov
Other drugs for Advanced Biliary Tract Cancer
- FutibatinibTaiho · Phase 2/3
- TinengotinibTransThera Sciences (Nanjing), Inc. · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- IvosidenibServier Bio-Innovation LLC · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- D07001-softgelInnoPharmax Inc. · Phase 3
Coming up1
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Oct 2027 | A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026